Roche Holding AG (FRA:RHO)

Market Cap	321.31B +31.5%
Revenue (ttm)	68.05B +1.5%
Net Income	13.83B +55.6%
EPS	17.23 +55.6%
Shares Out	n/a
PE Ratio	23.23
Forward PE	18.02
Dividend	9.70 (2.36%)
Ex-Dividend Date	Mar 27, 2025

Volume	n/a
Average Volume	117
Open	410.60
Previous Close	411.00
Day's Range	410.60 - 410.60
52-Week Range	270.20 - 414.40
Beta	n/a
RSI	62.48
Earnings Date	Jan 29, 2026

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir...

• Industry: Pharmaceutical Preparations
• Founded: 1896
• Employees: 103,249
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RHO

Financial Performance

In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.

Financial numbers in CHF